GSK’s Nucala shows promise in nasal polyps
Nucala is the first anti-IL5 biologic to report positive Phase III results in patients with the condition says GSK
Read More
Tag: biologic
Long-term data backs safety and efficacy of GSK’s Nucala
GlaxoSmithKline has reported long-term safety data showing a sustained reduction in severe asthma attacks and improved asthma control in patients taking its biologic Nucala.
Read More
US regulators reject GSK’s Nucala for COPD
GlaxoSmithKline’s bid to expand the use of its biologic Nucala in the US to include patients with coronary pulmonary obstructive disorder (COPD) has hit a significant setback.
Read More
Final NICE nod for Janssen’s Tremfya
The National Institute for Health and Care Excellence (NICE) has now issued guidance recommending Janssen’s Tremfya as an option for treating plaque psoriasis in adults on the NHS.
Read More
GSK trials Benlysta/rituximab combo for lupus
GlaxoSmithKline has kicked off a Phase III trial assessing its lupus drug Benlysta in combination with rituximab in adult patients with the condition.
Read More
Teva’s subcutaneous asthma drug fails in PhIII
Teva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets.
Read More
EU approves AZ’ biologic Fasenra for severe asthma
AstraZeneca’s biologic Fasenra has been approved for use in Europe as an add-on maintenance treatment in patients with severe eosinophilic asthma.
Read More
FDA OK’s GSK’s asthma biologic for rare autoimmune disease
GlaxoSmithKline’s biologic Nucala has become the first therapy specifically approved in the US to treat a rare disease called eosinophilic granulomatosis with polyangiitis (EPGA).
Read More
US clears Sanofi’s ‘follow-on’ insulin Admelog
The US Food and Drug Administration has cleared Sanofi’s Admelog, the first follow-on biologic version of Eli Lilly’s Humalog, to manage mealtime blood sugar levels in people with diabetes.
Read More
NICE u-turn backs use of Teva’s asthma biologic
The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
Read More
EU approves LEO Pharma’s psoriasis biologic
A new treatment option has been approved in the European Union for patients with psoriasis, paving the way for access to a novel approach for those with moderate-to-severe forms of the disease who are candidates for systemic therapy.
Read More
Final NICE nod for GSK’s novel asthma biologic
Patients with a difficult-to-treat form of asthma should be getting routine access to GlaxoSmithKline’s novel asthma biologic Nucala on the NHS after final guidance backing its use was issued by cost regulators.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
